Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NKTR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNKTRNektar Therapeutics$29.28+1.7%$24.04$6.45▼$37.38$547.35M0.95676,553 shs405,032 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNKTRNektar Therapeutics+1.74%+8.65%+23.81%+164.00%+56.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNKTRNektar Therapeutics4.2864 of 5 stars3.44.00.04.22.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNKTRNektar Therapeutics 2.86Moderate Buy$88.33201.68% UpsideCurrent Analyst Ratings BreakdownLatest NKTR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025NKTRNektar TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $85.006/24/2025NKTRNektar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $100.006/24/2025NKTRNektar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$120.00(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNKTRNektar Therapeutics$98.43M5.66N/AN/A($1.27) per share-23.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNKTRNektar Therapeutics-$118.96M-$8.80N/AN/AN/A-163.17%-631.43%-58.21%11/6/2025 (Estimated)Latest NKTR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NKTRNektar Therapeutics-$3.13-$2.95+$0.18-$2.95$9.42 million$11.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNKTRNektar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNKTRNektar TherapeuticsN/A2.612.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNKTRNektar Therapeutics75.88%Insider OwnershipCompanyInsider OwnershipNKTRNektar Therapeutics5.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNKTRNektar Therapeutics22019.02 million18.02 millionOptionableNKTR HeadlinesRecent News About These CompaniesNektar Therapeutics (NASDAQ:NKTR) Trading Down 3.4% Following Insider SellingAugust 24, 2025 | americanbankingnews.comConnor Clark & Lunn Investment Management Ltd. Sells 362,571 Shares of Nektar Therapeutics $NKTRAugust 23, 2025 | marketbeat.comNektar Therapeutics $NKTR Shares Bought by US Bancorp DEAugust 23, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Insider Mark Andrew Wilson Sells 676 SharesAugust 22, 2025 | insidertrades.comNektar Therapeutics: Fairly Valued, High-Quality Biotech With Multiple Near-Term CatalystsAugust 22, 2025 | seekingalpha.comORIC Pharmaceuticals Appoints Kevin Brodbeck, PhD, as Chief Technical Officer to Support Advancement into Late-Stage Clinical DevelopmentAugust 18, 2025 | quiverquant.comQNektar Therapeutics (NASDAQ:NKTR) Position Trimmed by XTX Topco LtdAugust 18, 2025 | marketbeat.comNektar Therapeutics’ Earnings Call Highlights Growth PotentialAugust 14, 2025 | theglobeandmail.comNektar Therapeutics (NASDAQ:NKTR) Shares Sold by Altium Capital Management LLCAugust 14, 2025 | marketbeat.comPrimecap Management Co. CA Decreases Position in Nektar Therapeutics (NASDAQ:NKTR)August 9, 2025 | marketbeat.comNektar Therapeutics (NKTR) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comWhy Nektar Therapeutics Stock Popped 6% on FridayAugust 8, 2025 | fool.comNektar Q2 Loss Narrower Than Expected, Revenues Fall Y/YAugust 8, 2025 | zacks.comNektar Therapeutics Reports Q2 2025 Financial ResultsAugust 8, 2025 | msn.comCautious Hold Rating on Nektar Therapeutics Amid Promising Yet Uncertain Clinical DevelopmentsAugust 8, 2025 | tipranks.comNektar (NKTR) Q2 Revenue Falls 52%August 8, 2025 | fool.comNektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue EstimatesAugust 7, 2025 | zacks.comNektar Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | prnewswire.comCM Management LLC Increases Holdings in Nektar Therapeutics (NASDAQ:NKTR)August 6, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Shares Acquired by Mackenzie Financial CorpAugust 6, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Stake Reduced by Bank of New York Mellon CorpAugust 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNKTR Company DescriptionsNektar Therapeutics NASDAQ:NKTR$29.28 +0.50 (+1.74%) Closing price 08/27/2025 04:00 PM EasternExtended Trading$29.08 -0.20 (-0.67%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality Okta: Market Comes to a Boil, Explosive Upside Is Possible MongoDB Roars Back to Life: It’s Not Too Late to Buy More Amazon’s Chart Just Flashed a Pennant Pattern—Here’s What to Do Vertical Aerospace: An Analyst's Roadmap to a Potential Re-Rating AEHR Spikes 36% on Hyperscaler Order—Investors Should Take Notice From Debt to Liftoff: EchoStar's $23 Billion Catalyst Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.